New Delhi12 minutes ago
- copy link
Bharat Biotech claimed that Covaccine is safe and effective for children and adolescents aged 2 to 18 years. The company said that in the second and third phase studies of the vaccine, it has been found that immunity is increasing due to the vaccine. Between June 2021 and September 2021, the vaccine was tested on healthy children and adolescents aged 2-18 years, which was successful. The company presented the data of this study to the Central Drugs Standard Control Organization (CDSCO) in October 2021. After considering the results of the study, CDSCO approved the vaccine for emergency use for children and adolescents aged 6 to 18 years. The company’s study has been published in the journal Lancet Infectious Diseases.
Side effects seen in only 374 children
Bharat Biotech said that we did a Phase II and III study on the safety of the vaccine against children and adolescents aged 2 to 18 years. We wanted to make sure that there is no harm to children from this vaccine. How will the vaccine affect the immunity of children? Only 374 cases of side effects were reported in the study, most of which were minor.
After vaccination, most cases were found in people complaining of pain at the site of vaccination. The vaccine has been shown to be safe based on the data of about 50 million doses given to children in India.
President of Bharat Biotech said – we have succeeded in our goal
Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech said that we have developed a safe and effective COVID-19 vaccine for adults and children. We have prepared this as the primary vaccine and booster dose, glad we succeeded in our goal.